Hospitalisation among vaccine breakthrough COVID-19 infections

doi:10.1016/S1473-3099(21)00558-2

Comment

. 2021 Nov;21(11):1485-1486.

doi: 10.1016/S1473-3099(21)00558-2. Epub 2021 Sep 7.

Hospitalisation among vaccine breakthrough COVID-19 infections

Prerak V Juthani¹, Akash Gupta¹, Kelly A Borges², Christina C Price³, Alfred I Lee⁴, Christine H Won⁵, Hyung J Chun⁶

Affiliations

¹ Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA.
² Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT 06511, USA.
³ Section of Immunology, Yale School of Medicine, New Haven, CT 06511, USA.
⁴ Section of Haematology, Yale School of Medicine, New Haven, CT 06511, USA.
⁵ Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT 06511, USA.
⁶ Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT 06511, USA. Electronic address: hyung.chun@yale.edu.

PMID: 34506735
PMCID: PMC8423430
DOI: 10.1016/S1473-3099(21)00558-2

Comment

Hospitalisation among vaccine breakthrough COVID-19 infections

Prerak V Juthani et al. Lancet Infect Dis. 2021 Nov.

. 2021 Nov;21(11):1485-1486.

doi: 10.1016/S1473-3099(21)00558-2. Epub 2021 Sep 7.

Authors

Prerak V Juthani¹, Akash Gupta¹, Kelly A Borges², Christina C Price³, Alfred I Lee⁴, Christine H Won⁵, Hyung J Chun⁶

Affiliations

¹ Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA.
² Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT 06511, USA.
³ Section of Immunology, Yale School of Medicine, New Haven, CT 06511, USA.
⁴ Section of Haematology, Yale School of Medicine, New Haven, CT 06511, USA.
⁵ Section of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT 06511, USA.
⁶ Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT 06511, USA. Electronic address: hyung.chun@yale.edu.

PMID: 34506735
PMCID: PMC8423430
DOI: 10.1016/S1473-3099(21)00558-2

Erratum in

Correction to Lancet Infect Dis 2021; 21: 1485-86.
[No authors listed] [No authors listed] Lancet Infect Dis. 2022 Jan;22(1):e1. doi: 10.1016/S1473-3099(21)00708-8. Epub 2021 Nov 15. Lancet Infect Dis. 2022. PMID: 34793710 Free PMC article. No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. PVJ, AG, and KAB contributed equally to this Comment. The Yale University institutional review board approved the study (2000027792) and waived the need for informed consent.

Comment on

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, Fuller C, Irwin-Singer A, Davies D, Tut G, Lopez Bernal J, Moss P, Hayward A, Copas A, Shallcross L. Shrotri M, et al. Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23. Lancet Infect Dis. 2021. PMID: 34174193 Free PMC article.

Cited by

The heterogeneous mixing model of COVID-19 with interventions.
Duan M, Jin Z. Duan M, et al. J Theor Biol. 2022 Nov 21;553:111258. doi: 10.1016/j.jtbi.2022.111258. Epub 2022 Aug 28. J Theor Biol. 2022. PMID: 36041504 Free PMC article.
Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization.
Lamacchia G, Mazzoni A, Spinicci M, Vanni A, Salvati L, Peruzzi B, Bencini S, Capone M, Carnasciali A, Farahvachi P, Rocca A, Kiros ST, Graziani L, Zammarchi L, Mencarini J, Colao MG, Caporale R, Liotta F, Cosmi L, Rossolini GM, Bartoloni A, Maggi L, Annunziato F. Lamacchia G, et al. J Clin Immunol. 2022 Oct;42(7):1379-1391. doi: 10.1007/s10875-022-01325-2. Epub 2022 Jul 9. J Clin Immunol. 2022. PMID: 35809212 Free PMC article.
Progression to Critical Illness and Death in Patients With Breakthrough Hospitalizations.
Suleyman G, Fadel R, Alsaadi A, Sueng LN, Ghandour A, Alkhatib A, Singh T, Parsons A, Miller J, Ramesh M, Brar I, Alangaden G. Suleyman G, et al. Open Forum Infect Dis. 2022 Apr 21;9(7):ofac213. doi: 10.1093/ofid/ofac213. eCollection 2022 Jul. Open Forum Infect Dis. 2022. PMID: 35821729 Free PMC article.
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.
Elkrief A, Wu JT, Jani C, Enriquez KT, Glover M, Shah MR, Shaikh HG, Beeghly-Fadiel A, French B, Jhawar SR, Johnson DB, McKay RR, Rivera DR, Reuben DY, Shah S, Tinianov SL, Vinh DC, Mishra S, Warner JL. Elkrief A, et al. Cancer Discov. 2022 Feb;12(2):303-330. doi: 10.1158/2159-8290.CD-21-1368. Epub 2021 Dec 10. Cancer Discov. 2022. PMID: 34893494 Free PMC article. Review.
The "identikit" of subject with obesity and COVID-19 vaccine breakthrough.
Muscogiuri G, Barrea L, Verde L, Vetrani C, Savastano S, Colao A. Muscogiuri G, et al. EXCLI J. 2022 Apr 8;21:687-694. doi: 10.17179/excli2022-4864. eCollection 2022. EXCLI J. 2022. PMID: 35721580 Free PMC article.

See all "Cited by" articles

References

1. Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00289-9. published online June 23. - DOI - PMC - PubMed
1. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–1423. - PMC - PubMed
1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed
1. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021;384:1824–1835. - PMC - PubMed
1. Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021;384:1774–1775. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Supplementary concepts

Actions

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

[1] Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00289-9. published online June 23. - DOI - PMC - PubMed

[2] Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00289-9. published online June 23. - DOI - PMC - PubMed

[3] Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–1423. - PMC - PubMed

[4] Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–1423. - PMC - PubMed

[5] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed

[6] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed

[7] Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021;384:1824–1835. - PMC - PubMed

[8] Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021;384:1824–1835. - PMC - PubMed

[9] Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021;384:1774–1775. - PMC - PubMed

[10] Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021;384:1774–1775. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Hospitalisation among vaccine breakthrough COVID-19 infections

Affiliations

Hospitalisation among vaccine breakthrough COVID-19 infections

Authors

Affiliations

Erratum in

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical